Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Key FDA approvals in 2024

2024 authorizations kept a steady clip and gave people some new treatment options

Pharma’s memorable moments of 2024

The headlines and highlights that the C&EN team found noteworthy this year

In 2024, the Biosecure Act’s impact became clearer

The legislation aims to break ties between the US pharma industry and a few Chinese services firms

ADVERTISEMENT
ADVERTISEMENT
image name
Chemical Regulation

EPA seeks to protect workers from carbon tetrachloride

Final rule allows current uses of the toxic solvent with a new inhalation limit


EPA bans 2 common chlorinated solvents

Trichloroethylene and perchloroethylene phase-out plan includes exemptions for some critical applications

image name
Biochemistry

Wnt protein hitches a ride on exosomes

Researchers have found a domain on a Wnt protein that allows it to stick to vesicles


Dueling glue degraders take on sickle cell disease

Small molecules hint at a new treatment option for the inherited blood disorder

image name
Start-ups

Siftr Bio will design new ADC linkers

Spin-out from Ed Tate’s lab focuses on improving conjugate chemistry in the popular anticancer modality